Literature DB >> 18607005

Regulated programmed lysis of recombinant Salmonella in host tissues to release protective antigens and confer biological containment.

Wei Kong1, Soo-Young Wanda, Xin Zhang, Wendy Bollen, Steven A Tinge, Kenneth L Roland, Roy Curtiss.   

Abstract

We have devised and constructed a biological containment system designed to cause programmed bacterial cell lysis with no survivors. We have validated this system, using Salmonella enterica serovar Typhimurium vaccines for antigen delivery after colonization of host lymphoid tissues. The system is composed of two parts. The first component is Salmonella typhimurium strain chi8937, with deletions of asdA and arabinose-regulated expression of murA, two genes required for peptidoglycan synthesis and additional mutations to enhance complete lysis and antigen delivery. The second component is plasmid pYA3681, which encodes arabinose-regulated murA and asdA expression and C2-regulated synthesis of antisense asdA and murA mRNA transcribed from the P22 P(R) promoter. An arabinose-regulated c2 gene is present in the chromosome. chi8937(pYA3681) exhibits arabinose-dependent growth. Upon invasion of host tissues, an arabinose-free environment, transcription of asdA, murA, and c2 ceases, and concentrations of their gene products decrease because of cell division. The drop in C2 concentration results in activation of P(R), driving synthesis of antisense mRNA to block translation of any residual asdA and murA mRNA. A highly antigenic alpha-helical domain of Streptococcus pneumoniae Rx1 PspA was cloned into pYA3681, resulting in pYA3685 to test antigen delivery. Mice orally immunized with chi8937(pYA3685) developed antibody responses to PspA and Salmonella outer membrane proteins. No viable vaccine strain cells were detected in host tissues after 21 days. This system has potential applications with other Gram-negative bacteria in which biological containment would be desirable.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18607005      PMCID: PMC2453710          DOI: 10.1073/pnas.0803801105

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  40 in total

Review 1.  Use of live bacterial vaccine vectors for antigen delivery: potential and limitations.

Authors:  E Medina; C A Guzmán
Journal:  Vaccine       Date:  2001-02-08       Impact factor: 3.641

Review 2.  Bacterial infectious disease control by vaccine development.

Authors:  Roy Curtiss
Journal:  J Clin Invest       Date:  2002-10       Impact factor: 14.808

Review 3.  Bacteria-mediated DNA transfer in gene therapy and vaccination.

Authors:  Holger Loessner; Siegfried Weiss
Journal:  Expert Opin Biol Ther       Date:  2004-02       Impact factor: 4.388

4.  Accumulation of ppGpp in a relA mutant of Escherichia coli during amino acid starvation.

Authors:  I Török; C Kari
Journal:  J Biol Chem       Date:  1980-05-10       Impact factor: 5.157

Review 5.  Type 1/Type 2 immunity in infectious diseases.

Authors:  B Spellberg; J E Edwards
Journal:  Clin Infect Dis       Date:  2000-12-15       Impact factor: 9.079

Review 6.  Pneumococcal conjugate vaccine for young children.

Authors:  S Selman; D Hayes; L A Perin; W S Hayes
Journal:  Manag Care       Date:  2000-09

7.  Immune responses to recombinant pneumococcal PspA antigen delivered by live attenuated Salmonella enterica serovar typhimurium vaccine.

Authors:  Ho Young Kang; Jay Srinivasan; Roy Curtiss
Journal:  Infect Immun       Date:  2002-04       Impact factor: 3.441

8.  Immune responses dependent on antigen location in recombinant attenuated Salmonella typhimurium vaccines following oral immunization.

Authors:  Ho Young Kang; Roy Curtiss
Journal:  FEMS Immunol Med Microbiol       Date:  2003-07-15

9.  Simultaneous analyses of neutral carbohydrates and amino sugars in freshwaters with HPLC-PAD.

Authors:  Xianhao Cheng; Louis A Kaplan
Journal:  J Chromatogr Sci       Date:  2003-09       Impact factor: 1.618

Review 10.  [Clinical effectiveness of seven-valent pneumococcal conjugate vaccine (Prevenar) against invasive pneumococcal diseases: prospects for children in France].

Authors:  S Black; H Shinefield; R Cohen; D Floret; J Gaudelus; C Olivier; P Reinert
Journal:  Arch Pediatr       Date:  2004-07       Impact factor: 1.180

View more
  59 in total

1.  Salmonella synthesizing 1-dephosphorylated [corrected] lipopolysaccharide exhibits low endotoxic activity while retaining its immunogenicity.

Authors:  Qingke Kong; David A Six; Kenneth L Roland; Qing Liu; Lillian Gu; C Michael Reynolds; Xiaoyuan Wang; Christian R H Raetz; Roy Curtiss
Journal:  J Immunol       Date:  2011-06-01       Impact factor: 5.422

2.  Live attenuated Salmonella vaccines displaying regulated delayed lysis and delayed antigen synthesis to confer protection against Mycobacterium tuberculosis.

Authors:  María Dolores Juárez-Rodríguez; Jiseon Yang; Rebin Kader; Praveen Alamuri; Roy Curtiss; Josephine E Clark-Curtiss
Journal:  Infect Immun       Date:  2011-12-05       Impact factor: 3.441

3.  Live attenuated Salmonella vaccines against Mycobacterium tuberculosis with antigen delivery via the type III secretion system.

Authors:  María Dolores Juárez-Rodríguez; Lourdes T Arteaga-Cortés; Rebin Kader; Roy Curtiss; Josephine E Clark-Curtiss
Journal:  Infect Immun       Date:  2011-12-05       Impact factor: 3.441

4.  Α1-giardin based live heterologous vaccine protects against Giardia lamblia infection in a murine model.

Authors:  Gabriela Jenikova; Petr Hruz; Mattias K Andersson; Noa Tejman-Yarden; Patricia C D Ferreira; Yolanda S Andersen; Barbara J Davids; Frances D Gillin; Staffan G Svärd; Roy Curtiss; Lars Eckmann
Journal:  Vaccine       Date:  2011-10-12       Impact factor: 3.641

5.  A Novel Cre Recombinase-Mediated In Vivo Minicircle DNA (CRIM) Vaccine Provides Partial Protection against Newcastle Disease Virus.

Authors:  Yanlong Jiang; Xing Gao; Ke Xu; Jianzhong Wang; Haibin Huang; Chunwei Shi; Wentao Yang; Yuanhuan Kang; Roy Curtiss; Guilian Yang; Chunfeng Wang
Journal:  Appl Environ Microbiol       Date:  2019-07-01       Impact factor: 4.792

6.  Yersinia pestis with regulated delayed attenuation as a vaccine candidate to induce protective immunity against plague.

Authors:  Wei Sun; Kenneth L Roland; Xiaoying Kuang; Christine G Branger; Roy Curtiss
Journal:  Infect Immun       Date:  2010-01-19       Impact factor: 3.441

7.  Immunogenicity of a live recombinant Salmonella enterica serovar typhimurium vaccine expressing pspA in neonates and infant mice born from naive and immunized mothers.

Authors:  Huoying Shi; Shifeng Wang; Kenneth L Roland; Bronwyn M Gunn; Roy Curtiss
Journal:  Clin Vaccine Immunol       Date:  2010-01-06

8.  Construction of recombinant attenuated Salmonella enterica serovar typhimurium vaccine vector strains for safety in newborn and infant mice.

Authors:  Bronwyn M Gunn; Soo-Young Wanda; Dana Burshell; Caihong Wang; Roy Curtiss
Journal:  Clin Vaccine Immunol       Date:  2010-01-06

9.  Evaluation of regulated delayed attenuation strategies for Salmonella enterica serovar Typhi vaccine vectors in neonatal and infant mice.

Authors:  Huoying Shi; Shifeng Wang; Roy Curtiss
Journal:  Clin Vaccine Immunol       Date:  2013-04-24

10.  Live recombinant Salmonella Typhi vaccines constructed to investigate the role of rpoS in eliciting immunity to a heterologous antigen.

Authors:  Huoying Shi; Javier Santander; Karen E Brenneman; Soo-Young Wanda; Shifeng Wang; Patti Senechal; Wei Sun; Kenneth L Roland; Roy Curtiss
Journal:  PLoS One       Date:  2010-06-18       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.